Lipocine Inc. (LPCN) Expected to Announce Earnings of -$0.27 Per Share
Equities research analysts expect Lipocine Inc. (NASDAQ:LPCN) to report earnings of ($0.27) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Lipocine’s earnings, with the lowest EPS estimate coming in at ($0.28) and the highest estimate coming in at ($0.26). Lipocine posted earnings per share of ($0.16) during the same quarter last year, which suggests a negative year-over-year growth rate of 68.8%. The company is scheduled to announce its next earnings results on Tuesday, November 14th.
On average, analysts expect that Lipocine will report full year earnings of ($1.02) per share for the current year, with EPS estimates ranging from ($1.16) to ($0.85). For the next year, analysts forecast that the firm will post earnings of ($0.14) per share, with EPS estimates ranging from ($0.49) to $0.25. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Lipocine.
Lipocine (NASDAQ:LPCN) last announced its quarterly earnings data on Monday, August 7th. The specialty pharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.01).
LPCN has been the subject of several research analyst reports. ValuEngine lowered Lipocine from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. Roth Capital set a $38.00 price objective on Lipocine and gave the company a “buy” rating in a research note on Thursday, August 10th. Finally, Canaccord Genuity set a $11.00 price objective on Lipocine and gave the company a “buy” rating in a research note on Monday, August 7th.
Shares of Lipocine (NASDAQ:LPCN) traded down 0.27% during mid-day trading on Monday, hitting $3.70. The company had a trading volume of 63,472 shares. Lipocine has a one year low of $3.03 and a one year high of $5.33. The company’s 50-day moving average is $3.98 and its 200 day moving average is $4.04. The company’s market capitalization is $76.15 million.
A number of hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp lifted its stake in shares of Lipocine by 7.1% in the 1st quarter. Bank of New York Mellon Corp now owns 92,979 shares of the specialty pharmaceutical company’s stock valued at $362,000 after acquiring an additional 6,191 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in shares of Lipocine by 99.4% in the 1st quarter. Ameriprise Financial Inc. now owns 131,600 shares of the specialty pharmaceutical company’s stock valued at $513,000 after acquiring an additional 65,600 shares during the last quarter. Parametric Portfolio Associates LLC lifted its stake in shares of Lipocine by 27.1% in the 1st quarter. Parametric Portfolio Associates LLC now owns 58,739 shares of the specialty pharmaceutical company’s stock valued at $229,000 after acquiring an additional 12,518 shares during the last quarter. KCG Holdings Inc. lifted its stake in shares of Lipocine by 27.4% in the 1st quarter. KCG Holdings Inc. now owns 33,537 shares of the specialty pharmaceutical company’s stock valued at $131,000 after acquiring an additional 7,219 shares during the last quarter. Finally, LMR Partners LLP bought a new stake in shares of Lipocine in the 2nd quarter valued at about $173,000. 26.39% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “Lipocine Inc. (LPCN) Expected to Announce Earnings of -$0.27 Per Share” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/10/23/lipocine-inc-lpcn-expected-to-announce-earnings-of-0-27-per-share.html.
Lipocine Company Profile
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.